Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results
Provided By Globe Newswire
Last update: Apr 15, 2022
SAN DIEGO, April 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the fourth quarter and year ended December 31, 2021.
BlackRock Technology and Private Equity Term Trust
NYSE:BTX (2/21/2025, 8:04:35 PM)
After market: 7.64 -0.02 (-0.26%)7.66
-0.2 (-2.54%)
Find more stocks in the Stock Screener
